Aggressive chemotherapy and the selection of drug resistant pathogens.

Drug resistant pathogens are one of the key public health challenges of the 21st century. There is a widespread belief that resistance is best managed by using drugs to rapidly eliminate target pathogens from patients so as to minimize the probability that pathogens acquire resistance de novo. Yet s...

Full description

Bibliographic Details
Main Authors: Silvie Huijben, Andrew S Bell, Derek G Sim, Danielle Tomasello, Nicole Mideo, Troy Day, Andrew F Read
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-09-01
Series:PLoS Pathogens
Online Access:http://europepmc.org/articles/PMC3771897?pdf=render
id doaj-0adf4f17574f44b1b92dc7eb29d68381
record_format Article
spelling doaj-0adf4f17574f44b1b92dc7eb29d683812020-11-25T00:12:00ZengPublic Library of Science (PLoS)PLoS Pathogens1553-73661553-73742013-09-0199e100357810.1371/journal.ppat.1003578Aggressive chemotherapy and the selection of drug resistant pathogens.Silvie HuijbenAndrew S BellDerek G SimDanielle TomaselloNicole MideoTroy DayAndrew F ReadDrug resistant pathogens are one of the key public health challenges of the 21st century. There is a widespread belief that resistance is best managed by using drugs to rapidly eliminate target pathogens from patients so as to minimize the probability that pathogens acquire resistance de novo. Yet strong drug pressure imposes intense selection in favor of resistance through alleviation of competition with wild-type populations. Aggressive chemotherapy thus generates opposing evolutionary forces which together determine the rate of drug resistance emergence. Identifying treatment regimens which best retard resistance evolution while maximizing health gains and minimizing disease transmission requires empirical analysis of resistance evolution in vivo in conjunction with measures of clinical outcomes and infectiousness. Using rodent malaria in laboratory mice, we found that less aggressive chemotherapeutic regimens substantially reduced the probability of onward transmission of resistance (by >150-fold), without compromising health outcomes. Our experiments suggest that there may be cases where resistance evolution can be managed more effectively with treatment regimens other than those which reduce pathogen burdens as fast as possible.http://europepmc.org/articles/PMC3771897?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Silvie Huijben
Andrew S Bell
Derek G Sim
Danielle Tomasello
Nicole Mideo
Troy Day
Andrew F Read
spellingShingle Silvie Huijben
Andrew S Bell
Derek G Sim
Danielle Tomasello
Nicole Mideo
Troy Day
Andrew F Read
Aggressive chemotherapy and the selection of drug resistant pathogens.
PLoS Pathogens
author_facet Silvie Huijben
Andrew S Bell
Derek G Sim
Danielle Tomasello
Nicole Mideo
Troy Day
Andrew F Read
author_sort Silvie Huijben
title Aggressive chemotherapy and the selection of drug resistant pathogens.
title_short Aggressive chemotherapy and the selection of drug resistant pathogens.
title_full Aggressive chemotherapy and the selection of drug resistant pathogens.
title_fullStr Aggressive chemotherapy and the selection of drug resistant pathogens.
title_full_unstemmed Aggressive chemotherapy and the selection of drug resistant pathogens.
title_sort aggressive chemotherapy and the selection of drug resistant pathogens.
publisher Public Library of Science (PLoS)
series PLoS Pathogens
issn 1553-7366
1553-7374
publishDate 2013-09-01
description Drug resistant pathogens are one of the key public health challenges of the 21st century. There is a widespread belief that resistance is best managed by using drugs to rapidly eliminate target pathogens from patients so as to minimize the probability that pathogens acquire resistance de novo. Yet strong drug pressure imposes intense selection in favor of resistance through alleviation of competition with wild-type populations. Aggressive chemotherapy thus generates opposing evolutionary forces which together determine the rate of drug resistance emergence. Identifying treatment regimens which best retard resistance evolution while maximizing health gains and minimizing disease transmission requires empirical analysis of resistance evolution in vivo in conjunction with measures of clinical outcomes and infectiousness. Using rodent malaria in laboratory mice, we found that less aggressive chemotherapeutic regimens substantially reduced the probability of onward transmission of resistance (by >150-fold), without compromising health outcomes. Our experiments suggest that there may be cases where resistance evolution can be managed more effectively with treatment regimens other than those which reduce pathogen burdens as fast as possible.
url http://europepmc.org/articles/PMC3771897?pdf=render
work_keys_str_mv AT silviehuijben aggressivechemotherapyandtheselectionofdrugresistantpathogens
AT andrewsbell aggressivechemotherapyandtheselectionofdrugresistantpathogens
AT derekgsim aggressivechemotherapyandtheselectionofdrugresistantpathogens
AT danielletomasello aggressivechemotherapyandtheselectionofdrugresistantpathogens
AT nicolemideo aggressivechemotherapyandtheselectionofdrugresistantpathogens
AT troyday aggressivechemotherapyandtheselectionofdrugresistantpathogens
AT andrewfread aggressivechemotherapyandtheselectionofdrugresistantpathogens
_version_ 1725401876636106752